Skip to main content
Premium Trial:

Request an Annual Quote

Celemics, Strand Life Sciences Partner on Integrated Platform for NGS Analysis

NEW YORK – Celemics, a Korean manufacturer of targeted capture kits for next-generation sequencing, is combining its bioinformatics pipeline with analytics technology from Strand Life Sciences to help researchers go from sample to report using a single technology platform.

Under terms of the partnership, Bengaluru, India-based Strand Life Sciences will integrate the Celemics pipeline into its StrandOmics tertiary analysis platform. This integrated offering will include assay-specific variant filters to provide "guaranteed" clinical-grade data compliance for researchers in cancer and rare diseases, according to the companies.

"With our … track record of running NGS labs as well as interpretation support for genetic tests, we are excited to partner with Celemics to help bring their cancer, inherited cancer, and rare disease panels to the market," Strand Life Sciences CEO Ramesh Hariharan said in a statement.

"[Strand's] expertise in the engineering of NGS systems and long track record with the instrument and diagnostic companies will be valuable in accelerating our path to market integration," added Hyoki Kim, cofounder and CEO of Seoul, South Korea-based Celemics.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.